Nicotine & Tobacco in 2026
Combustible smoking is down. Vaping, pouches, and youth initiation are the new frontiers.
Body — 8 lenses: [Science: nicotinic acetylcholine receptor agonist; heterogeneous subtype effects. Biology: acute cardiovascular effects, chronic cardiovascular + cancer risk from combustion (not primarily nicotine), EVALI and vaping-associated lung injury history, nicotine-only harm profile. Psychology: rapid dependence, highest relapse rates of any SUD. Policy: FDA CTP, T21, flavor bans, SynZonic/Zyn scrutiny. Trends: youth vaping declining overall, pouches rising fast, combustibles at historic lows. Social: Big Tobacco’s documents legacy, truth® campaign. Treatment: FDA-approved — varenicline, bupropion, NRT (patch/gum/lozenge/inhaler/nasal spray). Harm reduction: step-down, combination NRT, vape-to-quit (controversial but supported by some evidence).]
Sources Cited
- 01.A
- 02.A
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionYouth & Young AdultsPeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.
A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.
Science & MedicineDoubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?
A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.
Science & MedicineTwo Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty
Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.